Home>>Signaling Pathways>> Others>> Others>>Methimazole
Methimazole Catalog No.GC10416

ICAM-1 inhibitor

Size Price Stock Qty
10mM (in 1mL DMSO)
In stock
In stock
In stock

Customer Review

Based on customer reviews.

Tel: (626) 353-8530 Email: sales@glpbio.com

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & SDS

View current batch:


Cell experiment [1,2]:

Cell lines

FRTL5 thyroid cell

Preparation method

The solubility of this compound in DMSO is >5.8 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

96 hrs


Methimazole inhibited FRTL5 thyroid cell proliferation by inducing S-phase arrest of the cell cycle. Methimazole induced cell arrest in S phase. Methimazole induced a fall in the proportion of cells in both G0/G1 and G2/M phases. Treatment with methimazole caused an increase in the percentages and absolute counts of Treg lymphocytes. Treatment with methimazole significantly decreased the percentages and absolute counts of Th17 lymphocytes.

Animal experiment [3,4]:

Animal models

Male Sprague-Dawley rats

Dosage form

Intraperitoneal administration, 300 mg/kg


Methimazole (300 mg/kg)induced cell death predominantly in the mature ORNs and partially reduced olfactory sensitivity in the rats. Methimazole (20-40 mg/kg) given 30 min before the nephrotoxicant reduced nephrotoxicity induced by cephaloridine, DCVC or 2-BHQ. Methimazole reduced cisplatin-induced nephrotoxicity when given 30 min before and up to 4 hr after cisplatin. Methimazole (40 mg/kg) 30 min before cephaloridine (2 g/kg) significantly protected rats against cephaloridine-induced oxidation of renal nonprotein thiols.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.


[1]. Smerdely P, Pitsiavas V, Boyages S C. Methimazole inhibits FRTL5 thyroid cell proliferation by inducing S-phase arrest of the cell cycle[J]. Endocrinology, 1993, 133(5): 2403-2406.

[2]. Klatka M, Grywalska E, Partyka M, et al. Th17 and Treg cells in adolescents with Graves’ disease. Impact of treatment with methimazole on these cell subsets[J]. Autoimmunity, 2014, 47(3): 201-211.

[3]. Sakamoto T, Kondo K, Kashio A, et al. Methimazole‐induced cell death in rat olfactory receptor neurons occurs via apoptosis triggered through mitochondrial cytochrome c‐mediated caspase‐3 activation pathway[J]. Journal of neuroscience research, 2007, 85(3): 548-557.

[4]. Sausen P J, Elfarra A A, Cooley A J. Methimazole protection of rats against chemically induced kidney damage in vivo[J]. Journal of Pharmacology and Experimental Therapeutics, 1992, 260(1): 393-401.

Chemical Properties

Cas No. 60-56-0 SDF
Chemical Name 3-methyl-1H-imidazole-2-thione
Canonical SMILES CN1C=CNC1=S
Formula C4H6N2S M.Wt 114.17
Solubility ≥5.8mg/mL in DMSO Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
  • Molarity Calculator

  • Dilution Calculator

**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).



Methimazole (MMI) is an inhibitor of ICAM-1 (intercellular adhesion molecule-1) gene transcription via modulating the function of STAT1 (signal transducer and activator of transcription 1) [1].
ICAM-1 (intercellular adhesion molecule-1), also named as CD54, is a member of IGSF (immunoglobulin super-family adhesion molecule) which is expressed on endothelial cells and immune system cells [2]. It is encoded by ICAM-1 gene, ICAM-1 functions via binding to LFA-1 (lymphocyte function associated molecule-1) or Mac-1. It has shown that ICAM-1 abnormally expressed in patients with autoimmune thyroid diseases. Through modulating the function of STAT1 (signal transducer and activator of transcription 1), methimazole could inhibit the transcription of ICAM-1[1].
Methimazole is an inhibitor of ICAM-1 expression while H2O2 and IFN-γ both could heavily enhance the expression of ICAM-1. When tested with the modified FRTL-5 rat thyroid cells, using 500 μM methimazole pretreated the cells could inhibit the induction of ICAM-1 RNA by H2O2 and IFN-γ [1].
In tadpoles with methimazole treatment, the gene expression of thyroid hormone response was increased [3]. Through administering rats with methimazole, the CH (congenital hypothyroidism) offspring could be obtained for further research [4]. In the study, Sprague Dawley rats could be made as hypothyroid model for further research via giving 0.025% methimazole [5]. Using pregnant C57Bl/6 mice model, it was shown that methimazole could be used for mice or rat without causing gross external malformations [6].
1.Kim, H., et al., Methimazole as an antioxidant and immunomodulator in thyroid cells: mechanisms involving interferon-gamma signaling and H(2)O(2) scavenging. Mol Pharmacol, 2001. 60(5): p. 972-80.
2.Kojima, R., M. Kawachi, and M. Ito, Butein suppresses ICAM-1 expression through the inhibition of IkappaBalpha and c-Jun phosphorylation in TNF-alpha- and PMA-treated HUVEC. Int Immunopharmacol, 2014. 19(14): p. 00484-6.
3.Choi, J., et al., Unliganded thyroid hormone receptor alpha regulates developmental timing via gene repression as revealed by gene disruption in Xenopus tropicalis. Endocrinology, 2014. 2.
4.O'Hare, E., et al., Effects of thyroxine treatment on histology and behavior using the methimazole model of congenital hypothyroidism in the rat. Neuroscience, 2014. 20: p. 128-138.
5.Herwig, A., et al., A thyroid hormone challenge in hypothyroid rats identifies t3 regulated genes in the hypothalamus and in models with altered energy balance and glucose homeostasis. Thyroid, 2014. 24(11): p. 1575-93.
6.Mallela, M.K., et al., Evaluation of developmental toxicity of propylthiouracil and methimazole. Birth Defects Res B Dev Reprod Toxicol, 2014. 101(4): p. 300-7.